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Abstract
Background: Preventive cardiology has expanded beyond coronary heart disease towards prevention of a broader
spectrum of cardiovascular diseases. Ethnic minorities are at proportionately greater risk for developing
extracoronary vascular disease including heart failure and cerebrovascular disease.
Methods: We performed a cross sectional study of Latino and White hypertension patients in a safety-net
healthcare system. Framingham risk factors, markers of inflammation (hsCRP, LPpLA2), arterial stiffness (Pulse wave
velocity, augmentation index, and central aortic pressure), and endothelial function (brachial artery flow-mediated
dilatation) were measured. Univariate and multivariable associations between these parameters and an index of
extracoronary atherosclerosis (carotid intima media thickness) was performed.
Results: Among 177 subjects, mean age was 62 years, 67% were female, and 67% were Latino. In univariate
analysis, markers associated with carotid intima media thickness (IMT) at p < 0.25 included pulse wave velocity
(PWV), augmentation index (AIx), central aortic pressure (cAP), and LpPLA2 activity rank. However, AIx, cAP, and
LpPLA2 activity were not significantly associated with carotid IMT after adjusting for Framingham risk factors (all
p > .10). Only PWV retained a significant association with carotid IMT independent of the Framingham general risk
profile parameters (p = .016). No statistically significant interactions between Framingham and other independent
variables with ethnicity (all p > .05) were observed.
Conclusion: In this safety net cohort, PWV is a potentially useful adjunctive atherosclerotic risk marker independent
of traditional risk factors and irrespective of ethnicity.
Keywords: Pulse wave velocity hypertension, atherosclerosis, carotid intima media thickness, Latino, inflammatory
markers, augmentation index, central aortic pressure, C-reactive protein
Background
An emerging concept in cardiovascular disease (CVD)
prevention is a shift in focus from predicting isolated cor-
onary events to broader prediction of any CVD event.
This has led to derivation of a new Framingham CVD
risk profile [1] beyond the traditional score for predicting
10-year coronary disease events [2]. To illustrate this,
data from the National Health and Nutrition Examina-
tion Surveys compared the two instruments among US
men and women and found that just 3% of individuals
were at a high (>20%) predicted coronary disease risk,
whereas 18% were at high CVD risk when CVD death,
myocardial infarction, angina, stroke, transient ischemic
attack, peripheral arterial disease, and heart failure were
encompassed [3]. This broader focus on predicting CVD
risk might especially benefit ethnic minorities given
higher prevalence rates of non-coronary vascular disease
[4]. Although the prevalence of coronary disease is
higher for Whites versus minorities, total CVD rates are
higher among minorities, largely attributable to a higher
occurrence of stroke and heart failure [4].
At the same time, considerable efforts have been made
to improve the discriminative capacity of risk prediction
tools by adding new risk factors to the models. Markers
of inflammation, particularly high-sensitivity C-reactive
protein (hsCRP), and measures of vascular function have
received attention. The role of emerging markers has
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not been well explored for prediction of CVD beyond
coronary disease, and data are more limited among min-
ority populations. For instance, just 1% of subjects in
both derivation and validation cohorts of a study asses-
sing the additional predictive value of hsCRP were
Latino [5]. Although a greater prevalence of arterial
stiffness has been demonstrated in African Americans
[6], little is known about vascular function among Lati-
nos, the largest and fastest growing minority population
in the United States [7]. Given this background, we eval-
uated inflammatory and vascular function markers in a
safety-net population with chronic hypertension. We
hypothesized that regardless of ethnicity, pulse wave
velocity (PWV) would be associated with pre-clinical
carotid atherosclerosis beyond traditional risk factors.
Methods
Subject characteristics
The study sample consisted of 177 subjects recruited
from an electronic registry of hypertension patients cre-
ated as part of the Latinos Using Cardio Actions to
Reduce Risk (LUCHAR) program [8]. Patients in the
registry were regular patients at Denver Health, an inte-
grated urban safety net health system [9]. Data from the
registry were supplemented with chart review and
patient self-report during an enrollment interview.
Patients were eligible for the current study if they were
≥18 years of age, of either Latino or non-Latino White
ethnicity, actively receiving antihypertensive medication,
and had an established diagnosis of chronic hyperten-
sion. In addition, subjects had at least one other CVD
risk factor including diabetes, dyslipidemia, obesity,
chronic kidney disease, microalbuminuria, current
smoking, or age >55 for men or >65 for women. All
participants provided written informed consent in order
to participate in the study. Patients were evaluated con-
secutively during the enrollment period and excluded if
they had pre-existing CVD defined as myocardial infarc-
tion, prior percutaneous or surgical coronary revascular-
ization, stroke, cerebrovascular revascularization, or
peripheral arterial disease. Additional exclusions were
valvular heart disease, end-stage renal disease, inflamma-
tory disease, active substance abuse, or projected life
expectancy <12 months. Non-invasive vascular structure
and function markers as well as inflammatory biomar-
kers were obtained on a single day. The Colorado Multi-
ple Institutional Review Board approved the study
protocol.
Inflammatory markers
A venous plasma sample was obtained from all subjects.
Patients were asked to fast and refrain from smoking
from the night before their appointment. We chose two
markers of systemic inflammation, high sensitivity
C-reactive protein (hsCRP) because it has been studied
extensively as a risk factor5 and lipoprotein-associated
phospholipase A2 (Lp-PLA2) given its purported specifi-
city for inflammation localized to atherosclerotic plaque
including carotid arteries [10-13]. Levels of Lp-PLA2
mass and activity were measured (PLAC; diaDexus Inc,
South San Francisco, CA) by a dual monoclonal anti-
body immunoassay.13 Samples were assayed for hsCRP
with a high-sensitivity assay (hsCRP Flex®, Dimension
Vista). This assay was validated against the Roche Hita-
chi Modular assay and found to have acceptable preci-
sion and reproducibility [14].
Vascular function measures
All measurements were performed in a quiet room with
controlled ambient temperature. Blood pressure was
measured in duplicate in the supine position using the
non-dominant arm in all subjects. Brachial-ankle pulse
wave velocity (PWV) was derived from the pulse transit
time between and the estimated path length between
proximal and distal arterial sites expressed as cm/sec.
Applanation tonometry (HEM-9000AI Omron Health-
care, Bannockburn, Illinois) was performed at the radial
artery to derive the augmentation index (AIx) and cen-
tral aortic pressure (cAP). AIx was calculated as the dif-
ference between the first (ejection) and second
(reflected) peaks of the arterial waveform, expressed as a
percentage of the pulse pressure, where higher AIx
values reflect greater vascular stiffness.
One ultrasonographer assessed flow-mediated dilation
(FMD) of the brachial artery in the non-dominant arm,
which was immobilized and scanned above the antecu-
bital fossa using a 5-12 MHz linear array transducer
(Phillips Medical Systems model iE33, Bothell, WA).
Arterial images were obtained before (baseline) and after
(maximal) inflation of a cuff at pressures >40 mm Hg
above systolic blood pressure for five minutes. Longitu-
dinal images were scanned and captured (in mm) at end
diastole. FMD was defined as [maximal - baseline bra-
chial artery diameter] divided by baseline brachial artery
diameter × 100 and expressed as percentages.
Carotid intima-media thickness
Measures of maximal carotid IMT were obtained in the
supine position by a single ultrasonographer. Longitudi-
nal B-mode ultrasound images were obtained among
subjects with the head turned 45 degrees from the area
scanned. Gain settings were optimized to acquire far
wall arterial images and limit echogenicity of the lumen.
A linear array probe (Phillips Sonos 5500, Netherlands)
was used for all image acquisition. The sonographer
obtained 3 longitudinal views of both internal carotid
arteries for a total of 6 IMT images per subject as pre-
viously described [15]. The internal carotid artery was
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defined to include the bulb and the initial 10 mm of
vessel distal to separation of external from internal
arteries. High resolution images were stored digitally,
and read off-line by trained interpreters blinded to clini-
cal characteristics of study participants. Near and fall
wall thickness were calculated as the maximum distance
between the lines.
Statistical Analysis
Mean and standard deviations for all normally distributed
variables were calculated. Pulse wave velocity was nor-
malized after transformation by the relationship P-
inverse = - (1/PWV) - 0.0006)/0.00011) [16]. Carotid
IMT was the primary outcome variable. Pearson correla-
tion coefficients or Student’s t-test were used to assess
univariate relationships between carotid IMT and candi-
date independent variables. Multivariate linear regression
models were used to assess the association between caro-
tid IMT and the inflammatory, vascular stiffness, and
endothelial function variables after adjusting for variables
used in the Framingham general risk profile including
age, gender, systolic blood pressure, anti-hypertensive
medication use, total and HDL-cholesterol, diabetes, and
smoking status. Because all subjects were receiving anti-
hypertensive medications, this variable was not consid-
ered further. P-values < 0.05 were considered statistically
significant. Receiver operator characteristic curves to pre-
dict high carotid IMT as a dichotomous variable were
also constructed for Framingham risk score, PWV, and
AIx. We tested interactions with each independent vari-
able and ethnicity in another set of models to test the
hypothesis that the relationship between the outcome
variables and the independent variables would be similar
between Latino and non-Latino white subgroups. Follow-
ing data quality assurance measures, SAS Version 8.0
(Cary, NC) was used for all statistical analyses.
Results
Baseline characteristics of the sample are shown in
Table 1. The mean age was 62 years, two thirds were
female and two-thirds were Latino. Nearly half had dia-
betes. Consistent with a sample drawn from a safety net
institution, nearly half had not completed high school
and over 80% were unemployed or disabled. Mean
LpPLA2 was 173 ± 59 ng/ml. In contrast with hsCRP,
only 21% of subjects would be classified as high-risk,
using the LpPLA2 cut-point of >200 ng/ml [17]. Mean
hsCRP was 5.25 ± 6.65 mg/L and over 63% of the
cohort would be classified as high-risk using the recently
established cut-point of 2 mg/L used in the JUPITER
trial [18]. Univariate relationships between independent
variables and carotid IMT are shown in Table 2. The
inflammatory, and vascular function variables associated
with cIMT at p < 0.25 on univariate analysis were PWV,
AIx, cAP and LpPLA2 activity rank. PWV had the stron-
gest linear relationship (r = + 0.39, p < 0.0001) with car-
otid IMT (Figure 1). For high carotid IMT (>0.8 mm)
C-statistics assessing discrimination for PWV, AIx and
Framingham risk score (adjusting for age, gender, systo-
lic blood pressure, and ethnicity) were 0.72, 0.63, and
0.51 respectively. Results of the multiple linear regres-
sion analyses with standardised coefficients are shown in
Table 3. After adjusting for Framingham risk factors,
AIx, cAP, and LpPLA2 activity were no longer signifi-
cantly associated with carotid IMT (all p > .10). Only
PWV remained associated with carotid IMT indepen-
dent of the Framingham general risk profile parameters
(p = .016). Additional analyses indicated no statistically
Table 1 Patient Characteristics (n = 177)
Age, years 61.5 (9.7)
Female gender 66.7%
Ethnicity
Hispanic 66.7%
Non-Hispanic White 33.3%
Education
College graduate 8.5%
Higher education 19.3%
High school graduate 19.8%
Some high school 21.5%
No high school 31.1%
Employment Status
Employed 19.2%
Unemployed 46.9%
Disabled 33.9%
Body mass index, kg/m2 33.0 (6.7)
Blood pressure, mmHg 142.2 ± 22.1/81.7
± 12.3
Total cholesterol, mg/dl 181.5 (39.6)
Triglycerides, mg/dl 170.9 (105.2)
HDL cholesterol, mg/d 51.0 (12.8)
LDL-cholesterol, mg/dl 96.8 (33.3)
Diabetes Mellitus 49.2%
Current Smoker 22.0%
Framingham risk score* 11.6 (8.0), 1-53
LpPLA2† mass, ng/mL 173.5 (59.0)
LpPLA2 activity, nmol/min/mL 134.8 (34.3)
Central aortic pressure, mm Hg 59.5 (18.1)
Augmentation index 86.3% (12.7)
Pulse wave velocity, cm/sec 1723.3 (349)
Flow-mediated dilation 10.5% (8.1)
Carotid intima-media thickness, mm 0.95 (0.22)
Use of Hypertension Medication 90.4%
Use of Hydroxy-3-methylglutaryl Co-enzyme A
reductase inhibitors (statins)
59.9%
Values expressed as mean + standard deviation (SD) or as percentages (%).
hsCRP = high sensitivity C-reactive protein. *mean (SD) and range† LpPLA2 =
Lipoprotein-associated phospholipase A2.
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significant interactions between the Framingham risk
factors and other independent variables and ethnicity
(all p > .05) when predicting carotid IMT. For the inter-
action between PWV and ethnicity when predicting car-
otid IMT, the p-value was 0.518.
Discussion
In this cross-sectional study of a mixed-ethnicity
population, PWV, a measure of arterial stiffness, was
associated with preclinical carotid atherosclerosis inde-
pendent of Framingham risk factors. To our knowledge,
this is the first study to demonstrate that PWV is asso-
ciated with preclinical atherosclerosis among a Latino-
predominant population. Findings were similar in both
Latino and non-Latino White hypertensive subjects, sug-
gesting that measures of arterial stiffness could play a
role in CVD risk stratification within the growing US
safety net population. Moreover, two other arterial stiff-
ness measures, two inflammatory markers, and a tradi-
tional measure of endothelial function were not
associated with carotid intima media thickness.
Overall, most studies to date included patients with a
wide range of ages and underlying conditions but a lim-
ited range of race and ethnicity. In particular, none
included substantial numbers of Latinos. Moreover, very
few studies have compared the relative value of arterial
stiffness, inflammatory markers, and endothelial function
as correlates of CVD beyond isolated coronary disease
events. An epidemiological study of 2,191 elderly (age at
baseline 70-79) African American and White subjects,
assessed the predictive value of PWV, ankle brachial
index (ABI), and inflammatory markers (hsCRP,
Table 2 Univariate relationships with Carotid Intima
Media Thickness
N = 177 Carotid intima-media thickness
Correlation coefficient P
Age (years) 0.369 <.0001
Systolic blood pressure (mm Hg) 0.207 0.006
Total cholesterol (mg/dL) 0.054 0.476
HDL cholesterol (mg/dL) 0.096 0.210
Pulse wave velocity (cm/s) 0.389 <.0001
Augmentation Index (%) 0.123 0.130
Central aortic pressure (mm Hg) 0.254 0.005
hsCRP (mg/L) -0.004 0.959
LPPLA2 Mass rank 0.034 0.653
LPPLA2 Activity rank 0.110 0.149
Flow-mediated dilation (%) -0.087 0.270
Gender -0.170 0.007
Current Smoker 0.023 0.713
Diabetes -0.046 0.461
hsCRP = high sensitivity C-reactive protein. LpPLA2 = Lipoprotein-associated
phospholipase A2. HDL = high density lipoprotein.
Figure 1 Relationship of pulse wave velocity to carotid intima media thickness. The relationship between the inverse of the brachial-ankle
pulse wave velocity (PWV) in cm/second and the carotid intima media thickness in mm. P-inverse is - (1/PWV) - 0.0006)/0.00011). The resulting Z
(P-inverse) quantity has a mean of 0 and an SD of 1. The negative sign is used to ensure that correlations with PWV retain the same direction
when compared to P-inverse.
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interleukin-6, and TNF-a) to Framingham risk factors
[19]. The outcome variable was limited to coronary
disease events. PWV, ABI, and interleukin-6 were inde-
pendent predictors, and the model with the best discri-
minative capacity added both ABI and interleukin-6 to
Framingham factors. These results differ from our find-
ing that PWV was associated with preclinical cardiovas-
cular disease whereas inflammatory markers were not.
By contrast, a study of 558 patients with hypertension
and without baseline CVD, added PWV and FMD in
Cox multi-variable models that had occurrence of CVD
events including stroke as the outcome variable [20].
PWV was related to the occurrence of CVD events
while FMD was not, consistent with the results of the
current study in a similar hypertensive cohort. Our find-
ings are also consistent with the current consensus opi-
nion that PWV is the gold standard method for
assessing arterial stiffness [21].
Our results extend to a multi-ethnic population
findings of an association between arterial stiffness and
cardiovascular outcomes. In a recent meta-analysis,
Vlachopoulos et al [22] combined results of 17 longitu-
dinal studies and found a relative risk of 1.47 for cardio-
vascular events associated with each standard deviation
increase in PWV. These 17 studies varied in the degree
to which they accounted for Framingham risk factors
and in the degree to which they considered a full range
of non-coronary CVD outcomes. The most comprehen-
sive study was performed by Mitchell et al [16], and was
consistent with our study in that PWV, but not AIx or
cAP, was a significant predictor of CVD events indepen-
dent of the Framingham general risk profile parameters.
A number of factors should be considered in inter-
preting the results of the current investigation. This was
a cross-sectional study and was not powered to predict
CVD events. With a larger sample size, additional
vascular function variables could have reached statistical
significance. Relative to PWV, however, cAP and AIx
are less direct measures of arterial stiffness, more
sensitive to differences in heart rate and body size, and
may be more technically challenging to measure thereby
limiting their utility in risk stratification. The suggestion
that LpPLA2 may have greater predictive value than
hsCRP in high-risk populations deserves further explora-
tion since hsCRP values were uniformly elevated in this
safety net population. The absence of even a univariate
association between hsCRP and carotid IMT in the cur-
rent study is informative given the widespread use of
this marker in clinical practice. A recent guideline
affirms that measurement of hsCRP is not recom-
mended for risk stratification in asymptomatic higher-
risk adults, nor among older low-risk adults [23].
Confirmatory longitudinal studies comparing vascular
function and inflammatory markers as predictors of
CVD in samples with mixed race and ethnicity are
needed to better assess the strength and clinical implica-
tions of this association. In addition, the prognostic sig-
nificance of brachial-ankle PWV is less established
compared with carotid-femoral PWV. However,
brachial-ankle PWV, is more easily obtained and has
been shown to be highly correlated (r = 0.76, p <
0.0001) with carotid-femoral PWV values among hyper-
tensive patients [24]. Because of its strong relationship
with aortic pulse wave velocity, brachial-ankle PWV
measurements offers both practical and theoretic advan-
tages over the more frequently used carotid-femoral
method [25], though confirmatory studies with carotid-
femoral PWV are warranted. One strength of the cur-
rent analysis is its focus on a traditionally under-studied
safety net population. Evaluating sociodemographically
vulnerable subjects serves to broaden the applicability of
research findings to those individuals typically excluded
Table 3 Multivariate relationships with carotid intima-media thickness (n = 177)
Framingham factors
alone
Framingham factors
+ PWV
Framingham factors
+ AIx
Framingham factors
+ cAP
Framingham factors
+ LpPLA2
estimate P estimate P estimate P estimate P estimate P
Age 0.074 <.0001 0.045 0.016 0.073 <.0001 0.068 0.004 0.075 <.0001
Female Gender -0.111 0.002 -0.113 0.001 -0.127 0.002 -0.144 0.001 -0.113 0.002
Systolic BP 0.025 0.119 0.017 0.323 0.012 0.507 0.008 0.819 0.025 0.115
Total Cholesterol 0.014 0.397 0.003 0.862 0.005 0.772 0.005 0.809 0.018 0.296
HDL Cholesterol 0.018 0.303 0.022 0.205 0.024 0.201 0.024 0.245 0.017 0.322
Current Smoker 0.011 0.782 -0.003 0.937 0.023 0.596 0.007 0.893 0.018 0.659
Diabetes -0.008 0.796 -0.010 0.745 0.000 0.994 -0.025 0.562 -0.010 0.763
Pulse wave velocity 0.049 0.016
Augmentation Index 0.021 0.295
Central Aortic Pressure 0.034 0.384
LpPLA2 -0.013 0.441
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from research trials; in our study, the majority of parti-
cipants were women and Latinos in marked contrast to
typical cardiovascular trials [26].
Conclusions
Despite its strong association with cardiovascular mor-
tality among hypertensive patients [27] and endorsement
as a gold standard for vascular stiffness, the value of
PWV as a therapeutic target remains uncertain. None-
theless, our study demonstrates that PWV, in contrast
to inflammatory biomarkers, has predictive value for
preclinical atherosclerosis beyond the Framingham risk
profile among subjects of mixed ethnicity. Given
ongoing concerns about the inaccuracy of the Framing-
ham risk score in racial/ethnic minorities [28] and the
importance of considering overall CVD risk in such
individuals, PWV warrants further evaluation in both
epidemiologic and interventional studies.
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